Review
doi: 10.1007/82_2010_81.
Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways
Affiliations
- PMID: 20582531
- DOI: 10.1007/82_2010_81
Item in Clipboard
Review
Immunobiology of cancer therapies targeting CD137 and B7-H1/PD-1 cosignal pathways
Curr Top Microbiol Immunol.
2011.
Abstract
Cancer immunotherapy is finally entering a new era with manipulation of cosignaling pathways as a therapeutic approach, for which the principle was proved nearly two decades ago. In addition to CTLA-4, CD137 and B7-H1/PD-1 pathways are two new targets in the stage. CD137 pathway is costimulatory and its agonistic antibody delivers potent signal to drive T cell growth and activation. On the other hand, blockade of B7-H1/PD-1 pathway with antagonistic antibody has shown to protect ongoing T cell responses from impairment by immune evasion mechanism in cancer microenvironment. With these tools in hand, a mechanism-based design of combined immunotherapy with high efficacy is becoming a reality.
Similar articles
-
Clinical experiences with anti-CD137 and anti-PD1 therapeutic antibodies.Semin Oncol. 2010 Oct;37(5):508-16. doi: 10.1053/j.seminoncol.2010.09.008. Semin Oncol. 2010. PMID: 21074066 Review.
-
Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.Immunol Rev. 2008 Aug;224:166-82. doi: 10.1111/j.1600-065X.2008.00662.x. Immunol Rev. 2008. PMID: 18759926 Review.
-
B7-H1 pathway and its role in the evasion of tumor immunity.J Mol Med (Berl). 2003 May;81(5):281-7. doi: 10.1007/s00109-003-0430-2. Epub 2003 Apr 30. J Mol Med (Berl). 2003. PMID: 12721664 Review.
-
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion.Nat Med. 2002 Aug;8(8):793-800. doi: 10.1038/nm730. Epub 2002 Jun 24. Nat Med. 2002. PMID: 12091876
-
The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.Annu Rev Immunol. 2002;20:29-53. doi: 10.1146/annurev.immunol.20.091101.091806. Epub 2001 Oct 4. Annu Rev Immunol. 2002. PMID: 11861596 Review.
Cited by
-
Epstein-Barr virus-induced ectopic CD137 expression helps nasopharyngeal carcinoma to escape immune surveillance and enables targeting by chimeric antigen receptors.Cancer Immunol Immunother. 2022 Nov;71(11):2583-2596. doi: 10.1007/s00262-022-03183-8. Epub 2022 Mar 17. Cancer Immunol Immunother. 2022. PMID: 35299256 Free PMC article.
-
Regulatory T Cells Inhibit T Cell Activity by Downregulating CD137 Ligand via CD137 Trogocytosis.Cells. 2021 Feb 9;10(2):353. doi: 10.3390/cells10020353. Cells. 2021. PMID: 33572150 Free PMC article.
-
Bacterial Colonization in Patients with Chronic Lymphocytic Leukemia and Factors Associated with Infections and Colonization.J Clin Med. 2019 Jun 16;8(6):861. doi: 10.3390/jcm8060861. J Clin Med. 2019. PMID: 31208150 Free PMC article.
-
PD-1 regulates KLRG1+ group 2 innate lymphoid cells.J Exp Med. 2017 Jun 5;214(6):1663-1678. doi: 10.1084/jem.20161653. Epub 2017 May 10. J Exp Med. 2017. PMID: 28490441 Free PMC article.
-
CD137 signaling in Hodgkin and Reed-Sternberg cell lines induces IL-13 secretion, immune deviation and enhanced growth.Oncoimmunology. 2016 Apr 29;5(6):e1160188. doi: 10.1080/2162402X.2016.1160188. eCollection 2016 Jun. Oncoimmunology. 2016. PMID: 27471634 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
